Paper17513723
Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor.
Näslund TI and 7 others. J Immunol, 2007. Cited by 52 papers, by iCite.
Cite this record
ConductScience Library. Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor. Papers, record 17513723. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17513723
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor.
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenoviridae | Major topic |
| Canarypox virus | Major topic |
| Cancer Vaccines | Major topic |
| Immunization, Secondary | Major topic |
| Immunologic Memory | Major topic |
| Semliki forest virus | Major topic |
| T-Lymphocytes, Cytotoxic | Major topic |
| Viral Vaccines | Major topic |
| Animals | |
| Antigens, Neoplasm | |
| Cell Line, Tumor | |
| Epitopes, T-Lymphocyte | |
| Female | |
| Genetic Vectors | |
| Leukemia L1210 | |
| Mastocytoma | |
| Mice | |
| Mice, Inbred DBA | |
| Mice, Mutant Strains |
Source PubMed
Cited by32
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 52 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39384196 | Novel H-2Db-restricted CD8 epitope derived from mouse MAGE-type antigen P1A mediates antitumor immunity in C57BL/6 mice. | J Immunother Cancer | 2024 | https://conductscience.org/library/papers/39384196 | PubMed |
| 37834397 | Channeling the Natural Properties of Sindbis Alphavirus for Targeted Tumor Therapy. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37834397 | PubMed |
| 34479921 | Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy. | J Immunother Cancer | 2021 | https://conductscience.org/library/papers/34479921 | PubMed |
| 33637600 | TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism. | J Immunother Cancer | 2021 | https://conductscience.org/library/papers/33637600 | PubMed |
| 33322641 | Current Advances in Burkholderia Vaccines Development. | Cells | 2020 | https://conductscience.org/library/papers/33322641 | PubMed |
| 31292532 | Optimizing oncolytic virotherapy in cancer treatment. | Nat Rev Drug Discov | 2019 | https://conductscience.org/library/papers/31292532 | PubMed |
| 30546947 | Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. | Oncoimmunology | 2019 | https://conductscience.org/library/papers/30546947 | PubMed |
| 30524901 | Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. | Oncoimmunology | 2018 | https://conductscience.org/library/papers/30524901 | PubMed |
| 30465060 | An alphavirus-based therapeutic cancer vaccine: from design to clinical trial. | Cancer Immunol Immunother | 2019 | https://conductscience.org/library/papers/30465060 | PubMed |
| 30288352 | Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens. | Oncoimmunology | 2018 | https://conductscience.org/library/papers/30288352 | PubMed |
| 30135181 | Cytosolic Processing Governs TAP-Independent Presentation of a Critical Melanoma Antigen. | J Immunol | 2018 | https://conductscience.org/library/papers/30135181 | PubMed |
| 29205929 | Dendritic cell targeted HIV-1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8+ T cells. | Immun Inflamm Dis | 2018 | https://conductscience.org/library/papers/29205929 | PubMed |
| 29123081 | Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes. | Nat Commun | 2017 | https://conductscience.org/library/papers/29123081 | PubMed |
| 28918040 | Codon-Optimized P1A-Encoding DNA Vaccine: Toward a Therapeutic Vaccination against P815 Mastocytoma. | Mol Ther Nucleic Acids | 2017 | https://conductscience.org/library/papers/28918040 | PubMed |
| 28751892 | Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines. | Front Immunol | 2017 | https://conductscience.org/library/papers/28751892 | PubMed |
| 27119097 | Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy. | Mol Ther Oncolytics | 2015 | https://conductscience.org/library/papers/27119097 | PubMed |
| 26161423 | Human Tumor Antigens and Cancer Immunotherapy. | Biomed Res Int | 2015 | https://conductscience.org/library/papers/26161423 | PubMed |
| 26139534 | Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion. | EMBO J | 2015 | https://conductscience.org/library/papers/26139534 | PubMed |
| 25122792 | Kinetic and phenotypic analysis of CD8+ T cell responses after priming with alphavirus replicons and homologous or heterologous booster immunizations. | J Virol | 2014 | https://conductscience.org/library/papers/25122792 | PubMed |
| 25001465 | Therapeutic vaccines for cancer: an overview of clinical trials. | Nat Rev Clin Oncol | 2014 | https://conductscience.org/library/papers/25001465 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17513723
GET https://conductscience.org/api/papers/v1/17513723/cited_by?page=2